Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin

Samsung Medical Center

Status: Completed

Conditions: Curatively Resected Stage III Colon Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT00977717

2008-05-052

Details and patient eligibility

About

In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.

Full description

To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA isolation kit, and SNP polymorphisms will be evaluated.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged 18 or older
• curatively resected colon adenocarcinoma
• pathologically staged III
• adequate performance status
• adequate major organ functions
• to be treated with adjuvant FOLFOX chemotherapy
• written informed consent

Exclusion criteria

• those who disagree the study

Trial design

100 participants in 1 patient group

FOLFOX

Description:

Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy